Skip to content
JournalsWorldThe Global Research Discovery Platform
SCHOLARLY PUBLICATION ✓ Open Access

Buprenorphine Treatment Divide by Race/Ethnicity and Payment

Pooja Lagisetty, Ryan D. Ross, Amy S. B. Bohnert, Michael A. Clay, Donovan T. Maust

📄 Abstract

Buprenorphine Treatment Divide by Race/Ethnicity and PaymentOpioid mortality rates continue to increase throughout the United States 1 ; however, growth in buprenorphine hydrochloride treatment for opioid use disorder (OUD) might be limited to communities with higher income and low percentages of racial/ethnic minorities. 2 Buprenorphine, a partial opioid agonist, is 1 of 3 evidence-based medications for treating OUD and can legally be prescribed in office-based settings.To our knowledge, no national studies have examined the differences in the receipt of buprenorphine prescription by race/ethnicity and payment in office-based settings, in which most patients with buprenorphine prescription receive care. 3 In this article, we present changes in buprenorphine treatment at office-based visits in the United States since 2004 as well as the race/ethnicity and payment characteristics currently associated with its receipt.

📤 Share this page

Found this useful? Share it with your network.

✓ Link copied! Paste it on ResearchGate / Academia.edu